Amlodipine and Olmesartan Medoxomil Tablets
cGMP deviations
Every FDA drug recall initiated in 2022, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.
1,390 recalls, newest first.
cGMP deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
Subpotent drug
Non-sterility; bacterial contamination identified as Paenibacillus lautus.
Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.
Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared sildenafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.
Failed Impurities/Degradation Specifications: Out of specification results for related substances.
Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared sildenafil and tadalafil, ingredients found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.
Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.
Marketed Without An Approved NDA/ANDA: product was found to contain undeclared tadalafil and/or sildenafil, ingredients found in FDA approved products for the treatment of male sexual enhancement, making these unapproved drugs.
Marketed Without An Approved NDA/ANDA: product was found to contain undeclared tadalafil and/or sildenafil, ingredients found in FDA approved products for the treatment of male sexual enhancement, making these unapproved drugs.
Failed Impurities/Degradation Specifications: Lot not meeting specification for Unknown Max Related Compounds.
Labeling - product contains undeclared ethyl alcohol
Labeling - product contains undeclared ethyl alcohol
Foreign Matter identified as stainless steel microscopic wear particles mixed with punch lubricant oil and silicone particles from the dust cup
Failed Tablet Specifications: Recall of this drug product was voluntarily initiated by the manufacturer due to a market complaint, which stated that a tablet in the sealed bottle was twice larger in size when compared to the remaining tablets. This complaint is second of its kind.
Non-sterility
cGMP deviations: uncertainty of the adequacy of the validation of the test methods used to manufacture the products.
cGMP deviations: uncertainty of the adequacy of the validation of the test methods used to manufacture the products.
cGMP deviations: uncertainty of the adequacy of the validation of the test methods used to manufacture the products.
Marketed Without An Approved NDA/ANDA: product was found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.